1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Ocean Biomedical, Inc.

Ocean Biomedical, Inc.

OCEAW
Ocean Biomedical, Inc.US flagNASDAQ Global Market
0.03
USD
+0.03
- -
20.40MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-2
-62
-17
-114
-9
-31
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
-2
1
-11
-28
-33
-25
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
-2
105
-11
-91
-98
-92
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-5.47
Return on Common Equity (%)
- -
- -
- -
-0.89
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
13
16
9
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
166
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
34
34
27
Payables & Accruals
17
16
17
ST Debt
13
16
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-867.04%
7.55%
Free Cash Flow
- -
- -
-55.67%
Net Income, GAAP
- -
935.92%
-91.72%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
M. Michelle Berrey
Full Time Employees
7
Sector
Healthcare
Industry
Biotechnology
Address
Room 325, 55 Claverick Street Providence RI United States of America 02903
IPO Date
Nov 8, 2021
CIK
0001869974
Website
oceanbiomedical.com
Similar Companies
Genscript Biotech Corporation (1548.HK)
C4 Therapeutics, Inc. (CCCC)
Tempest Therapeutics, Inc. (TPST)
Hualan Biological Bacterin Inc. (301207.SZ)
IMV Inc. (IMVIQ)
XTL Biopharmaceuticals Ltd. (XTLB.TA)
Business
Ocean Biomedical, Inc. (NASDAQ:OCEA) is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic products targeting oncology, fibrosis, and infectious diseases. Founded in 2019 and headquartered at 55 Claverick Street, Room 325, Providence, Rhode Island, the company operates primarily in the United States through partnerships with leading research institutions and scientists worldwide, including Brown University affiliates; it functions as a subsidiary of Poseidon Bio, LLC. Its core pipeline includes oncology candidates such as OCX-253, an anti-Chi3l1 single-target monoclonal antibody (mAb), OCX-410, an anti-Chi3l1/PD-1 bi-specific antibody, and OCX-909, an anti-Chi3l1/CTLA-4 bi-specific antibody, all for non-small cell lung cancer and glioblastoma multiforme; fibrosis candidates like OCF-203, a small molecule targeting Chit1 for idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome; and infectious disease candidates for malaria comprising ODA-570 vaccine, ODA-611 anti-PfGARP humanized mAb therapeutic, and ODA-579 anti-PfGARP small molecule therapeutic, utilizing the WPDS platform. In October 2024, Ocean Biomedical secured a 22% fully-diluted ownership stake in Virion Therapeutics through a revised $9 million investment agreement involving cash and equity, amending a prior November 2023 arrangement and marking a strategic expansion into additional pharmaceutical assets; the company also debuted as a publicly traded entity in February 2023 via a business combination with Aesther Healthcare Acquisition Corp. and, as of April 2025, announced diversification into energy and digital asset sectors, including data center power infrastructure and Bitcoin investments, to generate recurring revenue supporting its biopharma growth.